Pacira Net Income From Continuing Ops from 2010 to 2025

PCRX Stock  USD 24.05  1.33  5.24%   
Pacira BioSciences, Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss is likely to outpace its year average in 2025. During the period from 2010 to 2025, Pacira BioSciences, Net Loss regression line of annual values had significance of  0.63 and arithmetic mean of (18,156,250). View All Fundamentals
 
Net Loss  
First Reported
2008-12-31
Previous Quarter
-143.5 M
Current Value
16 M
Quarterly Volatility
27.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pacira BioSciences, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pacira BioSciences,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 91.3 M, Selling General Administrative of 308.8 M or Total Revenue of 736 M, as well as many indicators such as Price To Sales Ratio of 1.18, Dividend Yield of 0.0014 or PTB Ratio of 1.06. Pacira financial statements analysis is a perfect complement when working with Pacira BioSciences, Valuation or Volatility modules.
  
Check out the analysis of Pacira BioSciences, Correlation against competitors.
For more information on how to buy Pacira Stock please use our How to Invest in Pacira BioSciences, guide.

Latest Pacira BioSciences,'s Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Pacira BioSciences, over the last few years. It is Pacira BioSciences,'s Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pacira BioSciences,'s overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Pretty Stable
   Net Income From Continuing Ops   
       Timeline  

Pacira Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(18,156,250)
Coefficient Of Variation(321.05)
Mean Deviation41,537,250
Median(13,716,000)
Standard Deviation58,290,048
Sample Variance3397.7T
Range245.1M
R-Value0.13
Mean Square Error3576.7T
R-Squared0.02
Significance0.63
Slope1,619,979
Total Sum of Squares50965.9T

Pacira Net Income From Continuing Ops History

2025-94.6 M
2024-99.6 M
2023M
202215.9 M
202142 M
2020145.5 M
2019-11 M

About Pacira BioSciences, Financial Statements

Pacira BioSciences, investors use historical fundamental indicators, such as Pacira BioSciences,'s Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pacira BioSciences,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-99.6 M-94.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pacira Stock Analysis

When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.